ProShare Advisors’s AtriCure ATRC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $200K | Sell |
7,013
-1,806
| -20% | -$61.6K | ﹤0.01% | 1582 |
|
|
2025
Q4 | $349K | Buy |
8,819
+543
| +7% | +$19.9K | ﹤0.01% | 1360 |
|
|
2025
Q3 | $292K | Sell |
8,276
-1,647
| -17% | -$56.7K | ﹤0.01% | 1440 |
|
|
2025
Q2 | $325K | Sell |
9,923
-326
| -3% | -$10.6K | ﹤0.01% | 1389 |
|
|
2025
Q1 | $331K | Sell |
10,249
-3,081
| -23% | -$114K | ﹤0.01% | 1349 |
|
|
2024
Q4 | $407K | Buy |
13,330
+4,385
| +49% | +$141K | ﹤0.01% | 1407 |
|
|
2024
Q3 | $251K | Buy |
+8,945
| New | +$220K | ﹤0.01% | 1583 |
|
|
2024
Q2 | – | Sell |
-8,371
| Closed | -$255K | – | 1862 |
|
|
2024
Q1 | $255K | Buy |
8,371
+659
| +9% | +$22.1K | ﹤0.01% | 1531 |
|
|
2023
Q4 | $275K | Buy |
7,712
+1,659
| +27% | +$61.7K | ﹤0.01% | 1440 |
|
|
2023
Q3 | $265K | Sell |
6,053
-6
| -0.1% | -$293 | ﹤0.01% | 1276 |
|
|
2023
Q2 | $299K | Buy |
6,059
+693
| +13% | +$31.9K | ﹤0.01% | 1273 |
|
|
2023
Q1 | $222K | Sell |
5,366
-500
| -9% | -$20.7K | ﹤0.01% | 1389 |
|
|
2022
Q4 | $260K | Buy |
+5,866
| New | +$245K | ﹤0.01% | 1321 |
|
|
2022
Q3 | – | Sell |
-5,121
| Closed | -$210K | – | 1754 |
|
|
2022
Q2 | $210K | Sell |
5,121
-3,280
| -39% | -$155K | ﹤0.01% | 1442 |
|
|
2022
Q1 | $552K | Sell |
8,401
-1,385
| -14% | -$89.7K | ﹤0.01% | 1222 |
|
|
2021
Q4 | $680K | Buy |
9,786
+4,043
| +70% | +$294K | ﹤0.01% | 1259 |
|
|
2021
Q3 | $399K | Sell |
5,743
-5,857
| -50% | -$451K | ﹤0.01% | 1350 |
|
|
2021
Q2 | $920K | Sell |
11,600
-83
| -0.7% | -$6.03K | ﹤0.01% | 1086 |
|
|
2021
Q1 | $765K | Buy |
11,683
+1,996
| +21% | +$123K | ﹤0.01% | 1148 |
|
|
2020
Q4 | $539K | Buy |
9,687
+4,325
| +81% | +$187K | ﹤0.01% | 1227 |
|
|
2020
Q3 | $214K | Buy |
5,362
+62
| +1% | +$2.63K | ﹤0.01% | 1385 |
|
|
2020
Q2 | $238K | Buy |
+5,300
| New | +$231K | ﹤0.01% | 1364 |
|
|
2014
Q4 | – | Sell |
-10,854
| Closed | -$160K | – | 1981 |
|
|
2014
Q3 | $160K | Sell |
10,854
-2,460
| -18% | -$39.2K | ﹤0.01% | 2044 |
|
|
2014
Q2 | $245K | Sell |
13,314
-11,146
| -46% | -$186K | ﹤0.01% | 2046 |
|
|
2014
Q1 | $460K | Buy |
+24,460
| New | +$501K | 0.01% | 1932 |
|
|
2013
Q4 | – | Sell |
-13,221
| Closed | -$145K | – | 1376 |
|
|
2013
Q3 | $145K | Buy |
13,221
+1,497
| +13% | +$14.8K | ﹤0.01% | 2305 |
|
|
2013
Q2 | $111K | Buy |
+11,724
| New | +$102K | ﹤0.01% | 2218 |
|
Other funds holding ATRC
HRCM
VPM
VCM
NAMI
ProShare Advisors's ATRC Position: Q1 2026 in Review
ProShare Advisors reduced its AtriCure (ATRC) stake by 20% in Q1 2026, selling an estimated $61.6K and leaving 7,013 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #1582.
ProShare Advisors first reported a position in ATRC in Q2 2013 and has held it in 27 quarters since. The position peaked at $920K in Q2 2021. 223 funds tracked by Wall St. Rank hold ATRC as of Q1 2026.
- ProShare Advisors held 7,013 shares of AtriCure worth $200K as of Q1 2026.
- ProShare Advisors sold 1,806 AtriCure shares in Q1 2026, an estimated $61.6K.
- AtriCure made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1582 holding.
- ProShare Advisors first reported a position in AtriCure in Q2 2013 and has held it in 27 quarters since.
- ProShare Advisors's AtriCure position peaked at $920K in Q2 2021.
- 223 funds tracked by Wall St. Rank held AtriCure as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.